Fundraising FoxQnovia
Richmond, US · Delaware corporation · 5 known investors
Find your way into Qnovia
Sign up to see every warm intro you have to Qnovia
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Qnovia team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Qnovia develops a portable, pre-filled vibrating mesh nebulizer (RespiRx) that delivers nicotine via ultrasonic nebulization without combustion, paired with a cloud-connected AI platform (Neblit) providing real-time behavioral support for smoking cessation. The company targets patients seeking nicotine replacement therapy in the pulmonary drug delivery and digital health space.
Founders & leadership
Board
Investors · 5
How we know: Evolution VC Partners's portfolio page · funding news · Not right? Tell us
__Twitter.png)
How we know: sandhillangels.com · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$41.3M disclosed across 3 rounds · 2022–2024
▶$14.2MraisedNov 2024 · 7 investors · PharmaceuticalsRule 506(b)
- Mario DanekExecutive Officer, Director
- Sean FaheyDirector
- Brian QuigleyExecutive Officer, Director
- Brian RianoDirector
- Gregg SmithDirector
- Offering amount
- $16M
- Amount sold
- $14.2M
- Proceeds to insiders
- $1.6M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedJun 2023 · 3 investors · BiotechnologyRule 506(b)
- Brian RianoDirector
- Mario DanekExecutive Officer, Director
- Brian QuigleyExecutive Officer, Director
- Gregg SmithDirector
- Sean FaheyDirector
- Offering amount
- $5M
- Amount sold
- $2.9M
- Proceeds to insiders
- $500K
- First sale
- May 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$24.2MraisedAug 2022 · BiotechnologyRule 506(b)
- Brian QuigleyDirector
- Mario DanekDirector
- Gregg SmithDirector
- Sean FaheyDirector
- Offering amount
- $30M
- Amount sold
- $24.2M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Qnovia.
Legal entities · 1
corporate structureIn the news
Frequently asked questions
- What does Qnovia do?
- Qnovia develops a portable, pre-filled vibrating mesh nebulizer (RespiRx) that delivers nicotine via ultrasonic nebulization without combustion, paired with a cloud-connected AI platform (Neblit) providing real-time behavioral support for smoking cessation. The company targets patients seeking nicotine replacement therapy in the pulmonary drug delivery and digital health space.
- Who founded Qnovia?
- Qnovia was founded by Mario Danek.
- Who are Qnovia's investors?
- Qnovia's investors include Evolution VC Partners, Gaingels, Sand Hill Angels, Blue Ledge Capital, Vice Ventures.
- How much funding has Qnovia raised?
- Qnovia has disclosed $41.3M raised across 3 rounds.
- Where is Qnovia headquartered?
- Qnovia is headquartered in Richmond, US.